Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Publication
, Journal Article
Piccini, JP; Garg, J; Hellkamp, A; Pieper, KS; Patel, MR
Published in: Eur Heart J
May 14, 2019
Duke Scholars
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
May 14, 2019
Volume
40
Issue
19
Start / End Page
1568
Location
England
Related Subject Headings
- Warfarin
- Rivaroxaban
- Humans
- Hemorrhage
- Cardiovascular System & Hematology
- Anticoagulants
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Piccini, J. P., Garg, J., Hellkamp, A., Pieper, K. S., & Patel, M. R. (2019). Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J, 40(19), 1568. https://doi.org/10.1093/eurheartj/ehy743
Piccini, Jonathan P., Jyotsna Garg, Anne Hellkamp, Karen S. Pieper, and Manesh R. Patel. “Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.” Eur Heart J 40, no. 19 (May 14, 2019): 1568. https://doi.org/10.1093/eurheartj/ehy743.
Piccini JP, Garg J, Hellkamp A, Pieper KS, Patel MR. Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2019 May 14;40(19):1568.
Piccini, Jonathan P., et al. “Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.” Eur Heart J, vol. 40, no. 19, May 2019, p. 1568. Pubmed, doi:10.1093/eurheartj/ehy743.
Piccini JP, Garg J, Hellkamp A, Pieper KS, Patel MR. Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2019 May 14;40(19):1568.
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
May 14, 2019
Volume
40
Issue
19
Start / End Page
1568
Location
England
Related Subject Headings
- Warfarin
- Rivaroxaban
- Humans
- Hemorrhage
- Cardiovascular System & Hematology
- Anticoagulants
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology